E11/podoplanin is critical in the early stages of osteoblast-to-osteocyte transitions (osteocytogenesis), however, the upstream events which regulate E11 expression are unknown. The aim of this study was to examine the effects of FGF-2 on E11-mediated osteocytogenesis and to reveal the nature of the underlying signaling pathways regulating this process. Exposure of MC3T3 osteoblast-like cells and murine primary osteoblasts to FGF-2 (10 ng/ml) increased E11 mRNA and protein expression (p < 0.05) after 4, 6, and 24 hr. FGF-2 induced changes in E11 expression were also accompanied by significant (p < 0.01) increases in Phex and Dmp1 (osteocyte markers) expression and decreases in Col1a1, Postn, Bglap, and Alpl (osteoblast markers) expression.
| INTRODUCTION
Osteocytes are derived from osteoblasts and are the most abundant cells, residing in mineralized bone of the adult skeleton. It has long been accepted that osteocytes are formed by the passive entrapment of redundant osteoblasts by osteoid synthesized by their close neighbors (Palumbo, Ferretti, & Marotti, 2004; Skerry, Bitensky, Chayen, & Lanyon, 1989) . The transition from the cuboidal-like osteoblastic morphology to a dendritic shape characteristic of an osteocyte is, however, a more active and tightly regulated process than originally recognized (for reviews see Dallas & Bonewald, 2010; FranzOdendaal, Hall, & Witten, 2006) .
The mechanisms which govern this osteoblast to osteocyte transition (osteocytogenesis) are generally unknown but fundamental studies by Bonewald and coworkers identified E11/podoplanin, a mucin-type transmembrane glycoprotein, as the earliest osteocyte marker protein expressed during osteocytogenesis (Zhang et al., 2006) . Furthermore, E11 triggers actin cytoskeletal dynamics (Staines et al., 2016) , which are required for dendrite formation and transient E11 knockdown blocks dendrite elongation (Zhang et al., 2006) . E11 glycoprotein is not unique to bone and is ubiquitously expressed by many tissues in which it has a range of regulatory functions including cell development, differentiation and invasiveness, epithelial-mesenchymal transition, and oncogenesis (Astarita, Acton, & Turley, 2012; Martín-Villar, Yurrita, Fernández-Muñoz, Quintanilla, & Renart, 2009; Thiery, 2002; Wicki & Christofori, 2007) . Owing to its wide tissue expression, it is now recognized by several names which include podoplanin in kidney podocytes, T1α in alveolar type 1 epithelial cells, PA2.26 in skin keratinocytes, gp38 in lymphoid organs, and E11 in lymphatic endothelial cells, osteoblasts, and osteocytes (Breiteneder-Geleff et al., 1997; Farr, Nelson, & Hosier, 1992; Ramirez et al., 2003; Scholl, Gamallo, Vilaró, & Quintanilla, 1999; Wetterwald et al., 1996) . The intracellular signaling mechanisms by which E11 influences dendrite formation involve the activation of the small GTPase, RhoA, and its downstream effector kinase, ROCK (Martín-Villar et al., 2006) . ROCK phosphorylates ezrin/moesin/radixin (ERM) and influences the actin cytoskeleton and subsequently cell shape (Martín-Villar et al., 2006 Sprague, Wetterwald, Heinzman, & Atkinson, 1996) . Much less, however, is known about the upstream regulatory events, specifically those that influence levels of E11 expression during osteocytogenesis. Nonetheless, clues from other model systems have indicated that fibroblast growth factor 2 (FGF-2) is able to change chondrocyte gene expression in vitro, including that of E11 (Chong et al., 2013) . FGF-2, one of the earliest members identified in the FGF polypeptide family, signals through FGF receptors that have intrinsic tyrosine kinase activity (Powers, Mcleskey, & Wellstein, 2000) . In addition to chondrocytes, FGF-2 is expressed by osteoblasts and is stored in the extracellular matrix where it regulates bone formation via influence on progenitor cell lineage commitment and/or osteoblast differentiation (Hurley, Marie, & Florkiewicz, 2002; Montero et al., 2000; Sabbieti et al., 1999; Xiao et al., 2010) . Indeed, mice deficient in Fgf2 have decreased bone mass and altered trabecular architecture whereas Fgf2 transgenic mice present with increased bone mineral density and cortical and trabecular thickness, as well as a variety of skeletal malformations including shortening and flattening of long bones (Coffin et al., 1995; Montero et al., 2000; Xiao et al., 2009 ).
Cognizant of FGF-2 stimulation of E11 expression in cartilage explants and osteoblast-like cells, we, therefore, hypothesized that FGF-2 may influence bone remodeling via increased osteoblast E11 expression and concomitant osteocyte dendrite formation (Chong et al., 2013; Gupta, Yoo, Hebert, Niger, & Stains, 2010) . Hence, the aims of this current study were to examine the effects of FGF-2 on E11 expression in osteoblasts during osteocytogenesis and to explore putative signaling pathways controlling this process.
| MATERIALS AND METHODS

| Animals
FGF-2-deficient mice (KO) were originally created by Tom Doetschman and obtained from the Jackson Laboratory, and were backcrossed onto a C57BL/6J wild-type (WT) background (Chong et al., 2013) .
Animal experiments were performed after obtaining ethical and statutory approval in accordance with local policy. Mice were maintained in accordance with UK Home Office guidelines for the care and use of laboratory animals. 50 µg/ml gentamicin (Invitrogen) at 37°C in a humidified atmosphere with 5% CO 2 and the medium was changed every 2-3 days. Cell viability was assessed using a commercially available Alamar Blue kit (Invitrogen) and cell cytotoxicity using an LDH assay according to the manufacturer's instructions (Promega, Southampton, UK).
| MC3T3 cell culture
| Primary osteoblast isolation
Primary calvarial osteoblasts were obtained from 3-day-old WT mice by serial enzyme digestion of dissected calvarial bones according to published procedure (Orriss, Hajjawi, Huesa, Macrae, & Arnett, 2014; Staines, Zhu, Farquharson, & Macrae, 2014 
| Signaling inhibitors
MC3T3 cells were incubated with appropriate concentrations (specific details in results) of the MEK1/2 inhibitor, U0126, the PI3K inhibitor, LY294002 (InvivoGen, Toulouse, France), and the p38 inhibitor, SB203580 (Cell Guidance Systems, Cambridge, UK). These inhibitors have been reported to be selective for these molecules (Choi et al., 2008; Hotokezaka et al., 2002; Macrae, Ahmed, Mushtaq, & Farquharson, 2007 Table S1 ) and the relative expression was calculated using the 2ΔCt method (Livak & Schmittgen, 2001 ). Figure S1 ). Wells were subsequently incubated with AlexaFluorconjugated donkey anti-goat secondary antibodies (Supplementary   Table S3 ) in the dark for 2 hr at RT. Glass coverslips were then mounted onto slides using ProLong Gold antifade reagent with DAPI (Thermo Fisher Scientific) for nuclei staining (Dobie, Macrae, Huesa, Van't Hof, & Ahmed, 2014) . The slides were finally visualized using a Leica DMRB fluorescence microscope and images were taken with a Leica DFC300 digital color camera (Leica, Milton Keynes, UK). 
| Western blotting
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| Immunohistochemistry
The knee joints of 6-week-old male FGF-2 KO and WT mice (Chong et al., 2013) , were fixed in 4% PFA for 24 hr before decalcification in 10% ethylenediaminetetraacetic acid (EDTA) pH 7.4 for approximately 3 weeks at 4°C with regular changes. Tissues were dehydrated and embedded in paraffin wax, using standard procedures, after which they were sectioned at 6 µm. Sections were dewaxed in xylene, rehydrated, and incubated at 37°C for 30 min in 1 mg/ml trypsin for antigen demasking. Endogenous peroxidases were blocked by treatment with 3% H 2 O 2 in methanol. E11 and sclerostin antibodies (Supplementary Table S2 ) were used with appropriate IgG controls and secondary antibodies (Supplementary Table S3 
| Phalloidin staining for histological sections
Femurs were decalcified as described above and then cryoprotected in 30% sucrose (w/v) at 4°C for 48 hr. The femora were cut in the mediolateral plane in serial longitudinal 20 μm thick-sections using a cryostat and thaw-mounted on gelatin-coated slides for processing. Slides were dried at room temperature for 45 min, washed in PBS twice for 5 min each, and incubated with 0.1%
Triton-X 100 (Sigma-Aldrich) for 30 min and then rinsed with PBS. 3 | RESULTS
| FGF-2 promotes osteoblast E11 gene and protein expression
Treatment of MC3T3 cells with 10 ng/ml FGF-2 for 4, 6, and 24 hr stimulated E11 mRNA expression in comparison to control cultures, at all time-points examined (p < 0.05, Figure 1a ). We observed a concomitant increase in E11 protein expression in these cells 
FIGURE 1
The effect of FGF-2 (10 ng/ml) on (a) E11 mRNA expression and (b) E11 protein expression in MC3T3 cells after 4, 6, and 24 hr challenge, where (+) is FGF-2 treated cell, and (−) is untreated control. The effect of FGF-2 (10 ng/ml) on (c) E11 mRNA expression and (d) E11 protein expression in primary osteoblast cells after 4, 6, and 24 hr challenge, where (+) is FGF-2 treated cell, and (−) is untreated control.
Results were normalized to the Atp5b housekeeping gene and β-actin for Western loading control. Data are presented as mean ± S.E.M for n = 3; *p < 0.05; ***p < 0.001 compared to untreated cells
| FGF-2 promotes osteoblast-osteocyte differentiation
In light of the increased E11 expression by FGF-2, we next examined the expression of known osteocyte and osteoblast marker genes to determine whether exposure of osteoblast-like cells to FGF-2 promoted osteocytic differentiation. In MC3T3 cells, FGF-2 increased the mRNA expression of the osteocyte marker Phex (phosphate regulating endopeptidase homolog, X-linked) at 4 (p < 0.01), 6 (not significant), and 24 (p < 0.001) hours (Figure 2a) . Similarly, Dmp1
(dentin matrix protein 1) expression was significantly increased at both 6 and 24 hr in MC3T3 cells (p < 0.001; Figure 2b ). In primary osteoblasts, both Phex and Dmp1 mRNA expressions were also increased by FGF-2 treatment, although the temporal changes were slightly different to those observed in the MC3T3 cells. Specifically, the stimulation of Phex expression by FGF-2 was greater at late time points whereas the up-regulation of Dmp1 was noted at earlier time points when compared with MC3T3 cells (Figures 2c and 2d ).
In contrast to the increased expression of osteocyte markers by (Figures 5c and 5d ).
| FGF-2 cell signaling in MC3T3 cells is mediated principally by phosphorylated ERK
FGF receptors (Fgfr) 1, 2, and 3, but not Fgfr4, were found to be expressed by MC3T3 cells (data not shown). FGF-2 treatment had no effect on Fgfr1 expression at all-time points studied (Figure 6a ), however, it reduced Fgfr2 (p < 0.01; Figure 6b ) and Fgfr3 (p < 0.05; increased Akt signaling may be a compensatory change to allow FGF-2 to promote E11 expression in the absence of full ERK activation (Figures 7b and 7c) . However, the combined inhibition of MEK and PI3K signaling by the inhibitors U0126 and LY294002, respectively, did not affect the ability of FGF-2 to enhance E11 protein expression (Figure 7i ).
| Deletion of FGF-2 in vivo results in dysfunctional osteocytogenesis
Finally, we used immunohistochemistry to examine whether FGF-2 KO mice exhibited altered skeletal E11 expression and distribution.
Unexpectedly, E11 staining in osteocytes situated within trabecular (Figure 8a-d) . To confirm and extend these results, we performed phalloidin staining of osteocytes in the cortical bone of FGF-2 KO and WT mice (Figures 9a and 9b ).
We observed a significant increase in cell body volume (p < 0.05, Figure 9c ) in concordance with our histological observations. Despite this, no differences in cell sphericity were observed (Figure 9d) .
Similarly, the total number of dendrites (Figure 9e ) and the dendrite volume ( Figure 9f ) were unchanged between FGF-2 KO and WT mice. We did, however, observe a significant decrease in average dendrite volume in FGF-2 KO in comparison to WT mice (p < 0.01; Figure 9g ), suggestive of dysfunctional osteocytogenesis in FGF-2 KO mice.
| DISCUSSION
The transmembrane glycoprotein E11, has recently been recognized to be an early driver of the osteoblast to osteocyte transition and the acquisition of the dendritic phenotype (Gupta et al., 2010; Zhang et al., 2006) . Consistent with previous data, here we reveal that FGF-2 is able to increase E11 expression and promotes osteocyte dendrite formation, likely independent of intracellular signaling pathways that may involve concomitant FGF-2 induced ERK activation.
Previous brief reports have shown that FGF-2 treatment of osteoblast-like cells induces an increase in E11 expression and the appearance of the osteocyte phenotype (Gupta et al., 2010; Miyagawa et al., 2014) . In this present study, we confirm and extend these and primary osteocytes isolated from long bones (Stern et al., 2012) . It is, therefore, likely that this redistribution of E11 within the cell is necessary for the transformation of the osteoblast from a cuboidal shape to the osteocytic phenotype characterized by stellate-like morphology with long dendritic processes (Zhang et al., 2006) . We also reveal that these morphological changes do not occur because of altered cell proliferation, nor do they precede cell death, therefore, highlighting the role for FGF-2 in regulating E11 expression and osteocyte differentiation in vitro. Results were normalized to the Atp5b housekeeping gene and β-actin for Western blotting loading control. Data are represented as mean ± S.E.M for n = 3. Data are analyzed via one-way ANOVA; p < 0.05 was considered to be significant. *p < 0.05
The intracellular effects of FGF-2 are activated via binding to its cell surface receptors, for example, FGFRs which have intrinsic receptor tyrosine kinase activity. Signaling pathways downstream of FGF-2-receptor binding are known to include ERK, p38, Akt, and PKC (Turner & Grose, 2010) . Of those examined in the present study, ERK showed the most robust activation in response to FGF-2 in MC3T3 osteoblast-like cells; although p38 and Akt phosphorylation was also significant.
Phosphorylation of ERK has been shown to mediate cell proliferation, differentiation, and matrix mineralization in human osteoblasts (Lai et al., 2001; Marie, Miraoui, & Severe, 2012) . The sustained activation of the MEK-ERK pathway and phosphorylation of ERK over long time periods suggests a central role for FGF-2 stimulation of cell differentiation (Murphy, Mackeigan, & Blenis, 2003; Pellegrino & Stork, 2006) . This is supported by studies that report the importance of ERK signaling in osteoblast initiation and commitment to the differentiation process (Lai et al., 2001) , and in osteocyte dendrite formation (Kyono, Avishai, Ouyang, Landreth, & Murakami, 2012) . Indeed, the conditional deletion of ERK ablates the formation of osteocytes with characteristic dendritic processes in vivo (Kyono et al., 2012) .
Somewhat surprisingly, however, the MEK inhibitor, UO126 was unable to block FGF-2's ability to promote E11 protein expression despite a significant reduction in ERK activation. Similar results were observed upon inhibition of PI3K/Akt and p38 signaling. These results suggest that alternative pathways may exist by which FGF-2 is able to enhance E11 expression and osteocyte formation. Such pathways may include the activation of p38 and Akt. Previous reports have indicated that activation of p38 is involved in osteoblast differentiation (Hu, Chan, Wang, & Li, 2003) whereas Akt phosphorylation is associated with cell survival (Debiais et al., 2004) . The down regulation of Akt by FGF-2 has, however, also been reported in human and mouse cells (Chaudhary & Hruska, 2001 ). In our hands, however, the dual inhibition of Akt and ERK activation by LY294002 and U0126, respectively, did not result in a block in E11 expression by FGF-2 and further work is required to unravel the signaling pathways that mediate FGF-2 effect on the up-regulation of E11 expression. The lack of JNK activation by FGF-2 in this study is consistent with JNK phosphorylation (P-JNK) mediating late osteoblast maturation (Matsuguchi et al., 2009 ).
Having shown that FGF-2 promotes E11 expression in MC3T3 osteoblast like-cells and murine primary osteoblasts, it was surprising to note that E11 protein expression by early osteocytes appeared to be increased in sections of bone from Fgf-2-deficient mice albeit no recognized that heparin-like glycosaminoglycans can regulate the signaling behavior of FGF-2 and, therefore, it is a possibility that in our cell culture experiments FGF-2 is more available to the cells due to a less mature extracellular matrix being formed (Padera, Venkataraman, Berry, Godavarti, & Sasisekharan, 1999) . Alternatively, the increased E11 staining intensity in the osteocytes from Fgf-2-deficient mice is maybe a compensatory response in an attempt to overcome the deficit in FGF-2 related promotion of the osteoblast to osteocyte transition, potentially through the upregulation of other members of the FGF family. Similarly, it may simply be a consequence of the significantly increased cell body volume observed in FGF-2 KO osteocytes. Indeed FGF-2 has been reported to decrease chondrocyte hypertrophy in a murine metatarsal organ culture model and as such, may play a similar role in the formation of the osteocyte (Mancilla, De Luca, Uyeda, Czerwiec, & Baron, 1998) . Our phalloidin staining also revealed a significant decrease in average dendrite length in FGF-2 KO mice compared to WT mice; a similar phenotype to that observed in our bone specific E11 conditional knockout mice (Staines et al., 2017) . This, therefore, suggests that the absence of FGF-2 in vivo results in dysfunctional osteocytogenesis.
In conclusion, these data taken together show that FGF-2 promotes the osteocyte phenotype and that this is mediated by increased E11 expression which is redistributed within the differentiating osteoblast. If further studies confirm this regulatory role for FGF-2 in osteocyte formation, we will be in a better position to understand the full repertoire of FGF-2 on bone cell function which may provide insights into the etiology of skeletal disorders such as osteoporosis and osteoarthritis.
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